Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of T0901317 in preparation of drugs treating or preventing hepatitis C

A hepatitis C virus and drug technology, which is applied in the field of medicine, can solve the problem that there is no application of T0901317 in anti-hepatitis C virus, and achieve the effect of improving the cure rate

Inactive Publication Date: 2013-04-24
WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are currently no applications of T0901317 against HCV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of T0901317 in preparation of drugs treating or preventing hepatitis C
  • Application of T0901317 in preparation of drugs treating or preventing hepatitis C
  • Application of T0901317 in preparation of drugs treating or preventing hepatitis C

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Evaluation of T0901317 Anti-Hepatitis C Virus Activity

[0036] 1. Experimental materials

[0037] 1.1 Cells, plasmids, viruses and drugs

[0038] Huh7.5.1 cells were donated by Dr.F.V.Chisari; plasmid pJFH1 containing the complete genome sequence of HCV type 2a JFH1 strain was donated by Prof. Dr. Takaji Wakita; plasmid pEGFP-N1 was purchased from Clontech; plasmid pGL4.70[hRLuc] was purchased from promega company. The virus JFH1-Luc-5AGFP with double reporter genes was prepared by our laboratory; T0901317 was purchased from sigma company.

[0039] 1.2 Reagents

[0040] DMEM medium was purchased from GIBCO Company; Renilla luciferase detection kit was purchased from Promega Company; anti-HCV NS3 mouse monoclonal antibody was purchased from Henan Bioengineering Technology Research Center; anti-GAPDH mouse monoclonal antibody was purchased from Beijing Zhongshan Golden Bridge Company; HRP-labeled goat anti-mouse secondary antibody was purchased from Thermo...

Embodiment 2

[0058] Embodiment 2: The research of T0901317 enters the influence of hepatitis C pseudovirus (HCVpp)

[0059] 1. Experimental materials

[0060] 1.1 Cells, viruses and drugs

[0061] Huh7.5.1 cells; T0901317; plasmid PNL4.3-R-E-Luc and plasmid pVpack-VSV-G containing the VSV viral envelope protein were kindly provided by the Division of AIDS Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The plasmids containing HCV1a and 1b envelope proteins were donated by Mr. Qi Zhongtian.

[0062] 1.2 Reagents

[0063] DMEM medium was purchased from GIBCO; transfection reagent Lipofectamine2000 was purchased from Invitrogen; Firefly luciferase detection kit was purchased from Promega.

[0064] 1.3 Experimental Instruments

[0065] The detector is a product of Promega Company.

[0066] 2. Experimental methods and results

[0067] 2.1 Compared with the live virus, the HCV pseudovirus has similar cell infection characteristics, which ca...

Embodiment 3

[0069] Example 3: Combination study of T0901317 and other drugs with anti-HCV activity.

[0070] 1. Experimental materials

[0071] 1.1 Cells, viruses and drugs

[0072] Huh7.5.1; virus JFH1-Luc-5AGFP; T0901317; CsA (purchased from Sigma Company) and MK-7009 (purchased from Zannan Company).

[0073] 1.2 Reagents

[0074] DMEM medium was purchased from GIBCO; Renilla luciferase detection kit was purchased from Promega.

[0075] 1.3 Experimental Instruments

[0076] The detector is a product of Promega Company.

[0077] 2. Experimental methods and results

[0078] 2.1 Divide Huh7.5.1 cells into 8×10 cells 3 Each cell / well was inoculated in a 96-well cell culture plate, cultured in a 37°C cell culture incubator for 14-18 hours, and then used after the cells grew into a monolayer. Cyclosporine A (CsA) or MK-70092-fold gradient dilution was added to the orifice plate as a control group for separate medication, and each group had 3 repetitions; in addition, 500 nM T0901317 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of T0901317 (N-(2, 2, 2-trifluoroethyl)-N-[4-[2, 2, 2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide) in preparation of drugs treating or preventing hepatitis C virus drugs. A drug without toxic concentration is chosen for an antiviral experiment, the influence of T0901317 on virus gene duplication is detected, and results show that the small molecule compound has significant antiviral activity and is dose dependent. Then, the T0901317 is employed to treat the hepatitis C pseudovirus system of different gene subtypes, and results show that the compound inhibits the virus entrance link at the early stage of a virus lifecycle. Also, the anti-virus capability of drug combination of T0901317 and other anti-HCV drugs is detected. T0901317 can inhibit 1a, 1b, and 2a genotype virus entrance, and has broad-spectrum antiviral activity and a novel target, while there is no anti-hepatitis C virus drug with entrance as the target yet clinically. And drug combination of T0901317 with other anti-hepatitis C virus drugs can achieve a good effect.

Description

technical field [0001] The present invention belongs to the technical field of medicine, and more specifically relates to a small molecule compound T0901317 (N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1- Application of hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide in the preparation of medicines for treating or preventing hepatitis C virus (HCV). Background technique [0002] Hepatitis C Virus (HCV), discovered in 1989, is the main pathogen causing non-A, non-B hepatitis after blood transfusion. About 170 million people worldwide are currently infected with HCV. HCV infection is distributed worldwide, the infection rate is about 3%, and 3 to 4 million new cases are added every year. According to the serological epidemiological survey data in my country, the positive rate of HCV in the general population is 3.2%. The main routes of transmission of HCV include blood transfusion or blood products, intravenous drug use, sexual contact, and mother-to-child tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/18A61P31/14A61P1/16
Inventor 陈绪林曾晶廖庆姣吴阳
Owner WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com